Clinuvel Pharmaceuticals (CLVLY)

[ghmm]

I don't agree with that. NICE is notorious for finding fault with new medicines being too expensive. Also look at what happened with PTC they got a positive recommendation but the pricing was not disclosed so reference pricing wouldn't be easily achieved. That is why its often one of the last to get reimbursement. Each government has their own policy. The Germany policy I've commented on earlier from my Intermune experience and Clinuvel did it all wrong IMO! Since there was (is) no reference drug for EPP and its an Orphan indication while still a complex process the German system is much more favorable. InterMune was the first to go through IQWIG and eventually went through arbitration but they had an initial price and sales before this! The process involved a mandatory reevaluation at set points (I believe it was 2 years or when costs to Germany system reached 50m Euro). I suspect the process was much harder being first and yet they started sales there immediately with one of the highest prices in the EU. Clinuvel would have been wise to hire/contract someone who new the process instead of wait what was it ~ 2 years to go there!